Showing 1 - 7 results of 7 for search 'Peter M. Haverty', query time: 0.03s Refine Results
  1. 1
    Super-enhancer acquisition drives oncogene expression in triple negative breast cancer.

    Super-enhancer acquisition drives oncogene expression in triple negative breast cancer. by Ryan Raisner, Russell Bainer, Peter M Haverty, Kelli L Benedetti, Karen E Gascoigne

    Published 2020-01-01
    Get full text
    Article
  2. 2
    Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens

    Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens by Jean-Philippe Fortin, Jenille Tan, Karen E. Gascoigne, Peter M. Haverty, William F. Forrest, Michael R. Costa, Scott E. Martin

    Published 2019-01-01
    Get full text
    Article
  3. 3
    Human biosample authentication using the high-throughput, cost-effective SNPtrace(TM) system.

    Human biosample authentication using the high-throughput, cost-effective SNPtrace(TM) system. by May M Y Liang-Chu, Mamie Yu, Peter M Haverty, Julie Koeman, Janet Ziegle, Marie Lee, Richard Bourgon, Richard M Neve

    Published 2015-01-01
    Get full text
    Article
  4. 4
    Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation

    Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation by Ryan Raisner, Samir Kharbanda, Lingyan Jin, Edwin Jeng, Emily Chan, Mark Merchant, Peter M. Haverty, Russell Bainer, Tommy Cheung, David Arnott, E. Megan Flynn, F. Anthony Romero, Steven Magnuson, Karen E. Gascoigne

    Published 2018-08-01
    Get full text
    Article
  5. 5
    Transposable element expression in tumors is associated with immune infiltration and increased antigenicity

    Transposable element expression in tumors is associated with immune infiltration and increased antigenicity by Yu Kong, Christopher M. Rose, Ashley A. Cass, Alexander G. Williams, Martine Darwish, Steve Lianoglou, Peter M. Haverty, Ann-Jay Tong, Craig Blanchette, Matthew L. Albert, Ira Mellman, Richard Bourgon, John Greally, Suchit Jhunjhunwala, Haiyin Chen-Harris

    Published 2019-11-01
    Get full text
    Article
  6. 6
    Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.

    Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. by Jeffrey J Wallin, Jane Guan, Kyle A Edgar, Wei Zhou, Ross Francis, Anthony C Torres, Peter M Haverty, Jeffrey Eastham-Anderson, Sabrina Arena, Alberto Bardelli, Sue Griffin, John E Goodall, Kyla M Grimshaw, Klaus P Hoeflich, Christopher Torrance, Marcia Belvin, Lori S Friedman

    Published 2012-01-01
    Get full text
    Article
  7. 7
    Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.

    Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. by Mark Merchant, John Moffat, Gabriele Schaefer, Jocelyn Chan, Xi Wang, Christine Orr, Jason Cheng, Thomas Hunsaker, Lily Shao, Stephanie J Wang, Marie-Claire Wagle, Eva Lin, Peter M Haverty, Sheerin Shahidi-Latham, Hai Ngu, Margaret Solon, Jeffrey Eastham-Anderson, Hartmut Koeppen, Shih-Min A Huang, Jacob Schwarz, Marcia Belvin, Daniel Kirouac, Melissa R Junttila

    Published 2017-01-01
    Get full text
    Article

Search Tools: